BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9698465)

  • 1. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system.
    Shimizu Y; Kamoi S; Amada S; Hasumi K; Akiyama F; Silverberg SG
    Gynecol Oncol; 1998 Jul; 70(1):2-12. PubMed ID: 9698465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
    Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma.
    Scholten AN; Smit VT; Beerman H; van Putten WL; Creutzberg CL
    Cancer; 2004 Feb; 100(4):764-72. PubMed ID: 14770433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.
    Gilks CB; Ionescu DN; Kalloger SE; Köbel M; Irving J; Clarke B; Santos J; Le N; Moravan V; Swenerton K;
    Hum Pathol; 2008 Aug; 39(8):1239-51. PubMed ID: 18602670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.
    Shimizu Y; Kamoi S; Amada S; Akiyama F; Silverberg SG
    Cancer; 1998 Mar; 82(5):893-901. PubMed ID: 9486579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.
    Veerman MM; van der Wurff AA; van de Water M; Kruitwagen RF; Feijen HW; Vos MC
    Int J Gynecol Pathol; 2009 Sep; 28(5):432-41. PubMed ID: 19696612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group.
    Yamamoto S; Kasajima A; Takano M; Yaegashi N; Fujiwara H; Kuzuya K; Kigawa J; Tsuda H; Kurachi H; Kikuchi Y; Sugiyama T; Tsuda H; Moriya T
    Int J Gynecol Pathol; 2011 Mar; 30(2):129-38. PubMed ID: 21293288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma].
    Penault-Llorca F; Levrel O; Clémenson A; Kwiatkowski F; Pomel C; Fouilhoux G; De Latour M; Curé H; Déchelotte P; Fonck Y; Dauplat J
    J Gynecol Obstet Biol Reprod (Paris); 2000 Oct; 29(6):548-54. PubMed ID: 11084461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological classification and grading of primary ovarian carcinoma: experience of the ARTAC ovarian study group.
    Vacher-Lavenu MC; Le Tourneau A; Duvillard P; Godefroy N; Pinel MC
    Bull Cancer; 1993 Feb; 80(2):135-41. PubMed ID: 8173164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma.
    Akslen LA; LiVolsi VA
    Cancer; 2000 Apr; 88(8):1902-8. PubMed ID: 10760768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Needle biopsy of hepatocellular carcinoma: assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. Group d'Etude et de Traitement du Carcinoma Hépatocellulaire.
    Chapel F; Guettier C; Chastang C; Rached AA; Mathieu D; Tepper M; Beaugrand M; Trinchet JC
    Cancer; 1996 Mar; 77(5):864-71. PubMed ID: 8608476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reproducibility of histological parameters employed in the novel binary grading systems of endometrial cancer.
    Gemer O; Uriev L; Voldarsky M; Gdalevich M; Ben-Dor D; Barak F; Anteby EY; Lavie O
    Eur J Surg Oncol; 2009 Mar; 35(3):247-51. PubMed ID: 18775628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of morphometric nuclear grade of endometrial carcinoma.
    Salvesen HB; Iversen OE; Akslen LA
    Cancer; 1998 Sep; 83(5):956-64. PubMed ID: 9731900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma.
    Kennedy AW; Biscotti CV; Hart WR; Tuason LJ
    Gynecol Oncol; 1993 Sep; 50(3):334-8. PubMed ID: 8406197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type.
    Stefansson IM; Salvesen HB; Immervoll H; Akslen LA
    Histopathology; 2004 May; 44(5):472-9. PubMed ID: 15139995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.